Abstract
Secukinumab is a recombinant, high-affinity, fully humanized IgG monoclonal antibody that selectively binds and neutralizes interleukin-17A (IL-17A). IL-17A is a “master cytokine” that mediates the pathogenesis of psoriasis, so neutralizing it clears psoriasis. Two new double-blind, placebo-controlled, parallel-group, phase 3 trials examined secukinumab treatment of plaque psoriasis. ERASURE compared two injected doses of secukinumab (150 mg or 300 mg) with placebo in 738 patients; FIXTURE compared the secukinumab doses with …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
